FDA Approves Omidubicel for Patients with Hematologic Malignancies

On April 17, the U.S Food and Drug Administration (FDA) approved omidubicel-onlv for use in adult and pediatric patients (12 years of age and older) with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.

For more information read the FDA announcement.

Posted 4/19/2023